Immunosuppressive monoclonal antibodies: current and next generation.
Clin Microbiol Infect
; 17(12): 1759-68, 2011 Dec.
Article
em En
| MEDLINE
| ID: mdl-21995285
ABSTRACT
Monoclonal antibodies (mAbs) are well-established therapeutics, as evidenced by the large number of Food and Drug Administration-approved mAbs for the treatment of cancers, and inflammatory or autoimmune diseases, and for the prevention and treatment of solid organ transplant rejection. Although, in many cases, mAbs have improved patient survival, they are also associated with an increased incidence of opportunistic infections. We review here the current and next generation of mAbs and the risks that infectious disease specialists should be aware of.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doenças Autoimunes
/
Infecções Oportunistas
/
Doenças Inflamatórias Intestinais
/
Rejeição de Enxerto
/
Imunossupressores
/
Anticorpos Monoclonais
/
Neoplasias
Limite:
Humans
País/Região como assunto:
America do norte
Idioma:
En
Revista:
Clin Microbiol Infect
Ano de publicação:
2011
Tipo de documento:
Article